From Alphastreet - Earnings Decoded. Market Intelligence Delivered · AlphaStreet Newsdesk · · 1m
Acadia Pharmaceuticals Stock Plummets After Clinical Failure
Acadia Pharmaceuticals shares drop 8.6% after remlifanserin trial misses primary endpoint
In brief
Acadia Pharmaceuticals shares drop 8.6% after remlifanserin trial misses primary endpoint Remlifanserin clinical trial failure impacts Acadia's pipeline expansion and stock price Originally reported by Alphastreet - Earnings Decoded. Market Intelligence Delivered.
Stock Tumbles 8.6%
ACADIA Pharmaceuticals shares dropped 8.6% Thursday to close at $23.25 after its remlifanserin clinical study failed to meet its primary endpoint.
Clinical Trial Misses Goal
The company's remlifanserin, an investigational therapy, missed its main clinical trial goal, causing a significant setback for the biotech's pipeline expansion.
Pre-Market Drop
Shares initially fell 10% in pre-market trading before closing down 8.6% after the news.
Market Reaction
Trading volume reached 2.0 million shares as investors reassessed Acadia's development portfolio after the clinical failure.
Pipeline Impact
The setback raises questions about Acadia's pipeline depth beyond its existing commercial products and future development strategies.
Investor Concerns
Investors demand clearer paths to profitability and diversified revenue streams as Acadia navigates the clinical setback.
The essence
Remlifanserin clinical trial failure impacts Acadia's pipeline expansion and stock price
